Financial Performance - Revenue for Q3 2024 reached 3,212,811,697.13 yuan, a year-on-year increase of 10.02%[3] - Net profit attributable to shareholders in Q3 2024 was 308,396,080.13 yuan, a year-on-year decrease of 12.62%[3] - Total assets as of the end of Q3 2024 were 23,570,041,501.34 yuan, a year-on-year decrease of 10.98%[3] - Total operating revenue for the current period is 8,817,275,052.00 yuan, an increase from 8,560,256,911.27 yuan in the previous period[24] - Operating profit for the current period is 1,627,236,356.80 yuan, up from 1,328,483,021.07 yuan in the previous period[24] - Net profit attributable to the parent company's shareholders is 1,421,799,112.63 yuan, compared to 1,139,038,016.10 yuan in the previous period[25] - Basic earnings per share (EPS) for the current period is 0.8028, up from 0.6430 in the previous period[25] - Total comprehensive income for the current period is 1,430,086,645.22 yuan, compared to 1,107,456,956.68 yuan in the previous period[25] - Net profit for the current period is 1,369,206,716.49 yuan, compared to 1,134,523,142.41 yuan in the previous period[25] - Total comprehensive income attributable to the parent company's shareholders is 1,478,341,755.57 yuan, up from 1,112,499,103.26 yuan in the previous period[25] Revenue Breakdown by Service and Region - Laboratory services revenue for the first three quarters of 2024 was 5,218,670,210.75 yuan, a year-on-year increase of 2.95%[4] - CMC (small molecule CDMO) services revenue for the first three quarters of 2024 was 1,976,627,679.48 yuan, a year-on-year increase of 3.29%[4] - Revenue from North American clients in the first three quarters of 2024 was 573,067.48 million yuan, a year-on-year increase of 4.29%[5] - Revenue from Chinese clients in the first three quarters of 2024 was 132,879.79 million yuan, a year-on-year decrease of 12.14%[5] - Revenue from European clients (including the UK) in the first three quarters of 2024 was 152,731.20 million yuan, a year-on-year increase of 15.74%[5] - The company's overseas laboratories and factories saw a revenue decline of 1.34% in the first three quarters of 2024, accounting for 12.78% of total revenue[5] New Orders and Growth - New orders in the first three quarters of 2024 increased by over 18% year-on-year, with CMC services new orders growing by over 30%[6] Cash Flow and Financial Position - Cash and cash equivalents decreased by RMB 3.86 billion, a 66.19% drop compared to the beginning of the year[10] - Prepaid expenses increased by RMB 7.76 million, a 43.59% rise due to higher prepayments for raw material purchases[10] - Other receivables grew by RMB 51.75 million, a 45.74% increase mainly due to higher tax refund subsidies[10] - Deferred tax assets increased by RMB 54.30 million, a 35.44% rise due to higher deferred tax assets related to deductible losses[10] - Investment income surged by RMB 567.42 million, a 1,158.41% increase due to gains from the disposal of non-current financial assets and convertible bond repurchases[10] - Fair value change losses decreased by RMB 62.32 million, a 155.03% drop due to reduced gains from biological assets and derivative financial instruments[10] - Asset disposal losses increased by RMB 23.92 million, a 9,732.09% rise due to higher non-current asset disposal losses[11] - Non-operating income decreased by RMB 2.19 million, a 64.56% drop due to reduced government subsidies[11] - Income tax expenses increased by RMB 66.25 million, a 35.54% rise due to higher profit[11] - Total assets decreased to 23.57 billion yuan from 26.48 billion yuan at the beginning of the period[21][22] - Current assets decreased to 7.10 billion yuan from 10.87 billion yuan at the beginning of the period[21] - Non-current assets increased to 16.47 billion yuan from 15.60 billion yuan at the beginning of the period[21] - Total liabilities decreased to 9.54 billion yuan from 13.24 billion yuan at the beginning of the period[22] - Current liabilities increased to 4.16 billion yuan from 3.65 billion yuan at the beginning of the period[22] - Non-current liabilities decreased to 5.39 billion yuan from 9.58 billion yuan at the beginning of the period[22] - Owner's equity increased to 14.03 billion yuan from 13.24 billion yuan at the beginning of the period[22] - Cash and cash equivalents decreased to 2.00 billion yuan from 5.92 billion yuan at the beginning of the period[21] - Accounts receivable increased to 2.27 billion yuan from 2.24 billion yuan at the beginning of the period[21] - Inventory increased to 1.20 billion yuan from 1.01 billion yuan at the beginning of the period[21] - Sales of goods and services received cash of 8,940,386,810.41 yuan, an increase from 8,345,874,274.78 yuan in the previous period[26] - Cash received from tax refunds was 417,480,501.78 yuan, up from 384,922,168.66 yuan in the previous period[26] - Total cash inflow from operating activities was 9,481,564,856.83 yuan, compared to 8,954,356,730.64 yuan in the previous period[26] - Cash paid for goods and services was 1,740,077,789.56 yuan, an increase from 1,602,776,669.59 yuan in the previous period[26] - Cash paid to employees and for employee benefits was 4,309,827,312.87 yuan, up from 3,912,340,413.31 yuan in the previous period[26] - Net cash flow from operating activities was 1,770,502,528.88 yuan, a decrease from 2,029,402,975.72 yuan in the previous period[26] - Net cash flow from investing activities was -897,439,031.21 yuan, an improvement from -1,807,866,341.75 yuan in the previous period[26] - Net cash flow from financing activities was -4,785,948,104.84 yuan, a significant decrease from 431,485,182.20 yuan in the previous period[27] - The net increase in cash and cash equivalents was -3,857,571,108.40 yuan, compared to 663,129,877.44 yuan in the previous period[27] - The ending balance of cash and cash equivalents was 1,931,543,560.63 yuan, down from 2,022,842,617.58 yuan in the previous period[27] Shareholder and Investment Information - The top shareholder, HKSCC NOMINEES LIMITED, holds 16.87% of the shares, totaling 301,501,968 shares[12] - China Bank holds 25,892,311 shares, accounting for 1.45% of the total shares[14] - Industrial and Commercial Bank of China holds 13,655,593 shares, accounting for 0.76% of the total shares[14] - The company acquired approximately 78.5% equity of Shanghai Jiyin Intelligent Technology Co., Ltd. for RMB 43 million[17] - The company completed the first tranche of equity transfer payment and obtained control of Shanghai Jiyin in July 2024[17] - All first batch of HKD 300 million zero-coupon convertible bonds due in 2026 have been repurchased or redeemed and canceled[18] - The second batch of RMB 1,916 million zero-coupon USD-settled convertible bonds due in 2026 were repurchased or redeemed and delisted in June 2024[18] - The company's subsidiary Pharmaron (Hong Kong) International Limited invested an additional USD 7 million in PharmaGend, holding 35% of its shares[18] - The company increased its investment in AstraZeneca Fund to RMB 191 million, accounting for 8.46% of the fund's total subscribed capital[18] - The company completed the repurchase of shares through centralized bidding on July 26, 2024[19] - The company adjusted the 2021, 2022, and 2023 A-share restricted stock incentive plans on August 28, 2024[19] Operating Costs and Expenses - Total operating costs for the current period are 7,773,877,243.72 yuan, up from 7,354,768,450.44 yuan in the previous period[24] - Research and development expenses for the current period are 332,252,436.76 yuan, up from 296,764,121.85 yuan in the previous period[24]

Financial Performance - The company's operating revenue for Q3 2024 was CNY 3,212,811,697.13, representing a 10.02% increase compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2024 was CNY 308,396,080.13, a decrease of 12.62% year-on-year[4]. - The adjusted net profit attributable to shareholders under non-IFRS was CNY 417,128,142.56, down 13.20% compared to the previous year[4]. - Revenue from laboratory services for the first three quarters of 2024 was CNY 5,218,670,210.75, with a gross margin of 44.76%, up 2.95% year-on-year[5]. - Revenue from CMC (small molecule CDMO) services was CNY 1,976,627,679.48, with a gross margin of 30.82%, reflecting a 3.29% increase year-on-year[5]. - The company reported a significant increase in other comprehensive income by 1,170.63%, reaching 51,712,554.95 CNY compared to -4,830,087.99 CNY at the beginning of the year[10]. - The total income tax expense increased by 35.54%, amounting to 252,668,803.97 CNY compared to 186,420,334.57 CNY in the same period last year[11]. - The company reported a basic earnings per share of ¥0.8028, up from ¥0.6430 in the previous period, representing an increase of approximately 24.8%[34]. Assets and Liabilities - The total assets at the end of Q3 2024 were CNY 23,570,041,501.34, a decrease of 10.98% from the end of the previous year[4]. - The company's total current assets decreased from RMB 10.874 billion at the beginning of the period to RMB 7.098 billion at the end of the period[26]. - Non-current assets increased from RMB 15.602 billion at the beginning of the period to RMB 16.472 billion at the end of the period, indicating growth in long-term investments[27]. - Total liabilities at the end of the period amounted to ¥9,543,999,010.21, a decrease from ¥13,238,666,497.83 at the beginning of the period[30]. - The company’s total non-current liabilities were ¥5,387,955,744.22, compared to ¥9,584,190,645.48 at the beginning of the period, indicating a significant reduction[30]. - The total number of common shareholders at the end of the reporting period is 76,716[12]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was CNY 1,770,502,528.88, down 12.76% year-on-year[4]. - Operating cash inflow for the current period reached CNY 8,940,386,810.41, an increase of 7.15% compared to CNY 8,345,874,274.78 in the previous period[35]. - Net cash flow from operating activities was CNY 1,770,502,528.88, down 12.73% from CNY 2,029,402,975.72 in the previous period[36]. - Cash inflow from investment activities totaled CNY 2,369,036,263.63, up from CNY 2,107,544,066.88 in the previous period[37]. - Net cash flow from investment activities was -CNY 897,439,031.21, an improvement from -CNY 1,807,866,341.75 in the previous period[37]. - Cash inflow from financing activities was CNY 793,674,688.64, down from CNY 1,445,088,087.27 in the previous period[38]. - Net cash flow from financing activities was -CNY 4,785,948,104.84, compared to a positive CNY 431,485,182.20 in the previous period[38]. Shareholder Information - The top 10 shareholders hold a combined 53.88% of the shares, with HKSCC NOMINEES LIMITED holding the largest share at 16.87%[12]. - The second-largest shareholder, Shenzhen Xinchongkang Investment Partnership, holds 14.59% of the shares[12]. - Pharmaron Holdings Limited, the third-largest shareholder, owns 10.10% of the shares[12]. - The total number of shares held by the top 10 unrestricted shareholders is 1,000,000,000[13]. - The largest unrestricted shareholder, HKSCC NOMINEES LIMITED, holds 301,501,968 shares[13]. - The total number of restricted shares at the beginning of the period was 64,260,000, with 6,986,213 shares released during the period[17]. - The number of shares held by the largest shareholder, Lou Xiaoqiang, decreased from 51,041,250 to 45,405,037 due to lock-up restrictions[17]. - The company has no preferred shareholders as of the reporting period[17]. - There are no known relationships or concerted actions among the top shareholders, except for specific connections mentioned[14]. Investments and Acquisitions - The company acquired approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. for a total investment of RMB 43 million, enhancing its capabilities in AI technology[19]. - The company successfully repurchased and canceled all of its first batch of USD 300 million zero-coupon convertible bonds, with a net amount raised of approximately RMB 3.776 billion from the issuance[20]. - The company invested an additional USD 7 million in PharmaGend Global Medical Services Pte. Ltd., increasing its stake to 35%[21]. - The company signed a strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd., committing to a total investment of RMB 91 million in the AstraZeneca Fund, representing 8.46% of the total subscription amount[23]. Other Financial Metrics - The company recognized a one-time loss of RMB 44,016 thousand due to business closure during the reporting period[46]. - The company reported a foreign exchange-related loss of RMB 32,273 thousand and unrealized gains of RMB (468,170) thousand from equity investments[46]. - The company experienced a 41.74% increase in credit impairment losses, totaling -24,846,953.62 CNY compared to -17,530,101.09 CNY in the previous year[11]. - The company reported a decrease in operating income by 64.56%, amounting to 1,201,135.59 CNY compared to 3,389,121.43 CNY in the same period last year[11]. - Research and development expenses increased to ¥332,252,436.76 from ¥296,764,121.85, marking a rise of approximately 11.9%[32].

Financial Performance - For the six months ended June 30, 2024, the company reported total revenue of RMB 5,604.5 million, a decrease of approximately RMB 35.7 million or 0.6% compared to the same period in 2023[8]. - The gross profit for the same period was RMB 1,848.1 million, reflecting a decline of 9.3% from RMB 2,037.4 million in the previous year[8]. - Profit attributable to equity holders of the parent increased by approximately 41.6% to RMB 1,113.4 million, compared to RMB 786.1 million for the six months ended June 30, 2023[9]. - The net cash flow from operating activities was approximately RMB 1,099.7 million, down 14.1% from RMB 1,280.2 million in the same period last year[9]. - The company achieved a net profit attributable to shareholders of RMB 1,113.4 million, an increase of 41.6% year-on-year[12]. - The company’s adjusted net profit under IFRS was RMB 690.3 million, a decrease of 25.9% year-on-year[12]. - The company reported a total of RMB 50,026,000 in current liabilities related to derivative financial instruments as of June 30, 2024, compared to RMB 26,931,000 as of December 31, 2023, showing an increase of approximately 85.5%[164]. - The total comprehensive income for the period was RMB 1,050,416 thousand, compared to RMB 821,211 thousand in the previous year, indicating a growth of 28%[124]. Revenue Breakdown - In Q2 2024, the company achieved revenue of RMB 2,933.7 million, representing a 9.9% increase compared to Q1 2024, indicating a recovery in the global biopharmaceutical investment and financing environment[11]. - Revenue from European customers (including the UK) was RMB 945.6 million, a year-on-year increase of 10.0%, accounting for 16.9% of total revenue[12]. - Revenue from North American customers was RMB 3,668.2 million, accounting for 14.1% of total revenue[12]. - The laboratory services segment generated revenue of RMB 3,371.2 million, a slight decrease of 0.3% year-on-year, with a gross margin of 44.0%[13]. - CMC (small molecule CDMO) services generated revenue of RMB 1,175.7 million, a decrease of 6.0% year-over-year; Q2 2024 revenue was RMB 593.6 million, reflecting a 2.0% increase from Q1 2024[14]. - Clinical research services achieved revenue of RMB 843.3 million, a 4.7% increase year-over-year; Q2 2024 revenue was RMB 451.7 million, up 15.4% from Q1 2024[15]. - The company's revenue from macromolecule and cell gene therapy services reached RMB 211.2 million, representing a 5.5% increase compared to the same period last year[16]. Customer Base and Market Position - The company served over 2,200 global customers in the first half of 2024, with multi-segment customers contributing RMB 3,987.9 million, representing 71.2% of total revenue[12]. - The company added over 360 new customers, contributing RMB 161.2 million to total revenue[12]. - 97% of the company's revenue comes from a large, diverse, and loyal repeat customer base, enhancing sustainable growth[31]. - The global biopharmaceutical industry is showing signs of recovery, with financing amounts for biotech companies returning to growth, indicating a preliminary revival in customer demand[32]. Operational Efficiency and Strategy - The company is focused on building a multi-therapy, full-process integrated service platform, aiming to become a global leader in drug development services[10]. - The company continues to strengthen its international capabilities to provide cross-disciplinary, cross-regional, and cross-border collaborative service solutions[10]. - The company is committed to improving management efficiency and service capabilities to meet market and customer demands[10]. - The company emphasizes continuous investment in technology and innovation, particularly in AI, to support its research and development capabilities[22]. - The company has established a comprehensive drug research and development service platform, enhancing its competitive advantage in the pharmaceutical industry[26]. Sustainability and Corporate Governance - The company’s scientific carbon targets were officially verified by SBTi, indicating a commitment to sustainability and carbon reduction initiatives[12]. - The company is committed to environmental protection, health, safety, and intellectual property rights, ensuring client trust and recognition[31]. - The company has established a DEI (Diversity, Equity, and Inclusion) management structure to ensure effective implementation of DEI policies across governance and operational levels[50]. - The company has actively responded to national initiatives for renewable energy use, with domestic parks already implementing green electricity applications and overseas parks utilizing biomass energy and photovoltaic power generation[63]. Human Resources and Employee Engagement - The company has established a comprehensive training system, including the Kanglong Academy, to enhance employee skills and research capabilities[31]. - The company emphasizes talent acquisition and retention, aiming to attract top drug development talent and enhance its internal training platform[38]. - The company has implemented a systematic training program for all employees and contractors to ensure understanding of company policies and job responsibilities[51]. - The company provides 10 days of paid parental leave and flexible part-time work arrangements in the UK and US locations[54]. Financial Position and Investments - As of June 30, 2024, the total current assets amounted to approximately RMB 7,071.2 million, compared to RMB 10,874.4 million as of December 31, 2023[20]. - The total liabilities to total assets ratio (leverage ratio) improved to 40.5% as of June 30, 2024, down from 50.0% as of December 31, 2023[20]. - The company completed the sale of its stake in Proteologix, Inc. to Johnson & Johnson for approximately USD 102 million, receiving a net payment of USD 86.195 million after transaction costs[22]. - The company has outstanding bank loans totaling RMB 5,179,140,000, with RMB 852,040,000 due within one year, compared to RMB 727,412,000 in the previous year, indicating a year-over-year increase of 17.1%[171]. Risks and Challenges - The company faces regulatory risks related to drug development and production, which could impact its operations if it fails to meet compliance requirements[44]. - The company is exposed to foreign exchange risks primarily related to USD, GBP, and EUR, with a significant portion of its revenue coming from USD-denominated sales[45]. - The competitive landscape is expected to intensify as more competitors enter the market, impacting various factors such as service quality and pricing[47].

Financial Performance - Total revenue for the six months ended June 30, 2024, was approximately RMB 5,604.5 million, a decrease of about RMB 35.7 million or 0.6% compared to the same period in 2023[2] - Profit attributable to equity holders of the parent company was approximately RMB 1,113.4 million, an increase of about 41.6% compared to RMB 786.1 million in the same period of 2023[2] - Net cash flow from operating activities was approximately RMB 1,099.7 million, a decrease of about 14.1% compared to RMB 1,280.2 million in the same period of 2023[2] - Gross profit for the six months ended June 30, 2024, was approximately RMB 1,848.1 million, a decrease of 9.3% compared to RMB 2,037.4 million in the same period of 2023[2] - The company recorded other income and gains of RMB 776.3 million, significantly up from RMB 131.7 million in the same period of 2023[3] - The group reported a pre-tax profit of RMB 1,226,851,000, compared to RMB 908,525,000 for the same period in 2023, marking an increase of approximately 35%[16] - The company’s adjusted net profit under non-IFRS was RMB 690.3 million, down from RMB 931.9 million in the previous year[53] Revenue Breakdown - For the six months ended June 30, 2024, total revenue reached RMB 5,604,463,000, a slight decrease of 0.6% compared to RMB 5,640,118,000 for the same period in 2023[16] - The laboratory services segment generated revenue of RMB 3,371,177,000, accounting for approximately 60% of total revenue, while the CMC (small molecule CDMO) services segment contributed RMB 1,175,747,000[16] - The clinical research services segment achieved revenue of RMB 843,269,000, reflecting an increase of 4.7% from RMB 805,193,000 in the prior year[16] - Revenue from North America was RMB 3,668,223,000, a decrease of 0.2% from RMB 3,675,469,000 in the previous year[18] - Revenue from Europe increased by 10% to RMB 945,577,000 from RMB 859,776,000 in 2023[18] - Revenue from mainland China decreased by 13.2% to RMB 842,603,000 from RMB 970,977,000 in 2023[18] Expenses and Costs - The group incurred administrative expenses of RMB 841,221,000, which is consistent with the previous year's expenses of RMB 845,440,000[16] - Research and development costs amounted to RMB 207,798,000, up from RMB 182,179,000 in the same period last year, representing an increase of approximately 14.1%[16] - The company reported a total of RMB 2,137,594,000 in employee costs, an increase from RMB 2,029,553,000 in 2023[27] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 25,340.7 million, compared to RMB 25,186.5 million as of December 31, 2023[7] - Current assets decreased to RMB 7,071.2 million from RMB 10,874.4 million as of December 31, 2023, indicating a significant reduction in liquidity[7] - Non-current liabilities decreased to RMB 5,414.3 million from RMB 9,584.2 million as of December 31, 2023, reflecting a reduction in long-term debt obligations[8] - Trade receivables as of June 30, 2024, totaled RMB 2,179.3 million, down from RMB 2,242.2 million at the end of 2023[30] - Trade payables amounted to RMB 503.0 million, an increase from RMB 412.2 million at the end of 2023[32] Dividends and Shareholder Returns - The company decided not to declare any interim dividend for the six months ended June 30, 2024[2] - The company declared a final dividend of RMB 0.2 per share for the year ended December 31, 2023, totaling RMB 353,963,000[28] - The company plans to distribute a final dividend of RMB 0.2 per share to A-share and H-share shareholders, with the record date set for July 8, 2024[160] Employee and Workforce - The company employed a total of 20,342 staff, with 89.7% in R&D, production technology, and clinical services[38] - As of June 30, 2024, the company employed 20,342 staff, an increase from 20,295 employees on December 31, 2023, indicating a growth in workforce[149] - The company has a workforce of 18,241 R&D, production technology, and clinical service personnel across China, the UK, and the US, ensuring high-quality service delivery[121] Strategic Initiatives and Growth - The company continues to focus on expanding its integrated pharmaceutical R&D services platform globally, enhancing its capabilities in drug innovation[12] - The company has signed new contracts with a total value that increased by over 15% compared to 2023[34] - The company is collaborating with over 650 hospitals and clinical trial centers across more than 140 cities in China, with ongoing projects exceeding 1,500[47] - The company has established a leading integrated pharmaceutical R&D service platform, providing comprehensive services for drug discovery, preclinical, and clinical development[106] - The company aims to enhance its integrated drug development service platform, focusing on small molecule research and expanding into large molecule and gene therapy services[129] Risks and Challenges - The pharmaceutical research and development outsourcing industry may experience slower growth due to fluctuations in investment sentiment, which could negatively impact the company's performance[138] - The company is at risk of losing qualified research and development personnel due to competition from pharmaceutical and biotech firms, which could affect service quality[138] - The company faces risks related to intellectual property protection, as unauthorized disclosure of client information could lead to significant reputational damage[141] - Regulatory compliance is critical, as failure to meet standards could result in operational suspension or penalties[142] - The company is exposed to foreign exchange risks, particularly with the US dollar, British pound, and euro, and will continue to engage in hedging transactions to reduce this risk[144] Incentive Plans - Under the 2021 A-share incentive plan, the maximum number of restricted A-shares to be issued is 1,741,950, representing approximately 0.10% of the total issued shares as of June 30, 2024[64] - The 2022 A-share incentive plan allows for the issuance of a maximum of 3,304,800 restricted A-shares, accounting for approximately 0.18% of the total issued shares as of June 30, 2024[76] - The 2023 A-share incentive plan was approved by shareholders on June 21, 2023, aiming to enhance corporate governance and retain key personnel[85] Acquisitions and Investments - The company has completed the sale of its stake in PROTEOLOGIX, INC. to Johnson & Johnson for approximately USD 102 million, receiving a net payment of USD 86.195 million after transaction costs[102] - The company has acquired approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. for a total investment of RMB 43.0 million, enhancing its capabilities in AI technology[102] - The company has signed a strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd. for a comprehensive investment in the AstraZeneca Fund, increasing its total investment in the fund to RMB 191 million, accounting for 8.46% of the total subscription[104]

证券代码：300759 证券简称：康龙化成 公告编号：2024-058 康龙化成（北京）新药技术股份有限公司 关于 2021 年 A 股限制性股票激励计划 第三个归属期归属条件成就 1、限制性股票拟归属数量：本次符合归属条件的激励对象共计 176 名，均 满足 100%归属条件，可归属的限制性股票数量为 371,460 股，占公司目前总股 本的 0.02%； 2、归属股票来源：公司向激励对象定向发行的本公司人民币 A 股普通股股 票； 但股票暂不上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 3、本次限制性股票归属条件成就之日为 2024 年 7 月 27 日； 4、根据公司 2021 年 A 股限制性股票激励计划（以下简称"本次激励计划"） 所有激励对象承诺，自每期限制性股票经董事会审议确定的归属条件成就之日起 6 个月内，不转让其所持有的当批次归属的全部限制性股票。因此公司申请本次 归属的限制性股票暂不上市，继续禁售至 2025 年 1 月 26 日。公司将延迟到禁售 期结束时向深圳证券交易所、中国证券登记结算有限责任公司深圳分 ...

Financial Performance - Revenue for the first half of 2024 reached $1.2 billion, representing a 15% year-over-year growth[2] - Net profit for the first half of 2024 was $180 million, a 12% increase compared to the same period last year[2] - Revenue for the first half of 2024 was RMB 5,604.46 million, a slight decrease of 0.63% year-over-year[15] - Net profit attributable to shareholders increased by 41.64% to RMB 1,113.40 million compared to the same period last year[15] - Adjusted non-IFRS net profit attributable to shareholders decreased by 25.93% to RMB 690.27 million[22] - The company expects full-year 2024 revenue to grow by 12-15%, reaching $2.5-2.6 billion[4] - Revenue from clients using multiple business segments accounted for 71.16% of total revenue, amounting to RMB 3,987.94 million[23] - Revenue from North American clients was RMB 3,668.22 million, accounting for 65.45% of total revenue, a slight decrease of 0.20% year-over-year[24] - Revenue from European clients (including the UK) increased by 9.98% to RMB 945.58 million, accounting for 16.87% of total revenue[24] - The company served over 2,200 global clients, with over 360 new clients contributing RMB 161.24 million, or 2.88% of total revenue[23] - Overseas subsidiaries delivered revenue of RMB 736.83 million, a 3.99% increase year-over-year, accounting for 13.15% of total revenue[25] - Laboratory services revenue for the first half of 2024 was 3,371.1768 million yuan, a slight decrease of 0.27% year-over-year, with a gross margin of 44.46%, down 0.59 percentage points[27] - CMC (small molecule CDMO) services revenue for the first half of 2024 was 1,175.7473 million yuan, a decrease of 6.04% year-over-year, with a gross margin of 28.30%, down 4.16 percentage points[28] - Clinical research services revenue for the first half of 2024 was 843.2694 million yuan, an increase of 4.73% year-over-year, with a gross margin of 12.55%, down 4.43 percentage points[30] - The company's large molecule and cell & gene therapy services generated revenue of 211.21 million yuan, a year-on-year increase of 5.49%, with Q2 2024 revenue reaching 119.78 million yuan, a 31.00% increase from Q1 2024[32] - The gross margin for large molecule and gene therapy CDMO services was -31.34% in H1 2024 due to ongoing construction and operational costs[32] - Revenue for the first half of 2024 was RMB 5,604,463,354.87, a slight decrease of 0.63% compared to the same period last year[48] - Operating costs increased by 3.96% to RMB 3,733,284,838.30, while sales expenses decreased by 3.02% to RMB 122,949,469.45[48] - R&D investment increased by 14.06% to RMB 207,797,841.87, reflecting the company's commitment to innovation[48] - Net cash flow from operating activities decreased by 14.10% to RMB 1,099,735,310.22, while net cash flow from financing activities saw a significant decrease of 825.39% to RMB -4,653,026,429.44[48] - Laboratory services accounted for the largest portion of revenue at RMB 3,371,176,816.35, with a gross margin of 44.46%[49] - CMC (small molecule CDMO) services revenue decreased by 6.04% to RMB 1,175,747,332.83, with a gross margin of 28.30%[49] - Clinical research services revenue increased by 4.73% to RMB 843,269,367.02, but the gross margin decreased by 4.43% to 12.55%[49] - The company's cash and cash equivalents decreased by 414.22% to RMB -3,506,304,159.12, primarily due to increased cash outflows from financing activities[48] - The company's investment income was RMB 634,095,077.59, accounting for 51.68% of total profit, mainly from the disposal of non-current financial assets and the redemption of convertible bonds[50] - Cash and cash equivalents decreased by RMB 350.63 million, a drop of 59.44% compared to the end of the previous year[52] - Accounts receivable increased by 1.01% to RMB 89 million, representing 9.48% of total assets[52] - Inventory increased by 1.34% to RMB 1.188 billion, accounting for 5.17% of total assets[52] - Fixed assets grew by 7.63% to RMB 7.398 billion, representing 32.17% of total assets[52] - Prepayments increased by RMB 8.2274 million, a rise of 46.20%, mainly due to increased prepayments for raw material procurement[52] - Long-term prepaid expenses increased by RMB 184.6683 million, a growth of 35.48%, primarily due to new operating lease property improvements[52] - Trading financial assets decreased by RMB 260.8939 million, a drop of 41.95%, mainly due to the redemption of low-risk bank wealth management products[52] - Long-term equity investment increased by 0.46% to RMB 734.2411 million, representing 3.19% of total assets[52] - The company's investment in the UK subsidiary, Kanglong (UK), accounted for 13.78% of the company's net assets, with a net profit of RMB 35.0722 million for the reporting period[54] - Total investment during the reporting period was RMB 2.7588 billion, an increase of 4.93% compared to the same period last year[57] - The company's financial assets measured at fair value had a total initial investment cost of 2,128,576,048.84 yuan, with a cumulative investment income of 573,579,951.29 yuan[58] - The company's other financial assets had an initial investment cost of 1,861,000,000.00 yuan, with a cumulative investment income of 10,888,387.92 yuan[58] - The company's other financial assets had an initial investment cost of 267,576,048.84 yuan, with a cumulative investment income of 562,691,563.37 yuan[58] - The company's financial derivatives had a cumulative fair value change of -27,649,894.23 yuan[58] - The company's entrusted wealth management products had a total amount of 132,500 million yuan, with an outstanding balance of 41,814.97 million yuan[60] - The company's forward foreign exchange contracts had an initial investment amount of 669,919.2 million yuan, with a fair value change of -5,180.51 million yuan[61] - The company's forward foreign exchange contracts had a final amount of 327,832.8 million yuan, accounting for 25.19% of the company's net assets at the end of the reporting period[61] - The company's actual loss from forward contracts and related foreign exchange transactions was 4,585.70 million yuan[61] - The company's financial derivatives are valued based on the market price of the USD/CNY spot rate at the end of each month[62] - The company's financial derivatives investment was approved by the board of directors on March 28, 2024, and by the shareholders' meeting on June 6, 2024[62] - Kanglong Chem (Ningbo) Technology Development Co., Ltd., a wholly-owned subsidiary, reported total assets of 2.297 billion yuan, net assets of 1.793 billion yuan, operating income of 871.86 million yuan, and net profit of 147.85 million yuan[66] Business Operations and Strategy - The company's CDMO business contributed $400 million, accounting for 33% of total revenue[2] - The company plans to expand its production capacity in the second half of 2024, with an investment of $200 million[4] - The number of active clients increased by 10% to 1,500, with 30% of revenue coming from new clients[2] - The company's gross margin remained stable at 35%, reflecting efficient cost management[2] - The company issued $300 million in zero-coupon convertible bonds due in 2026[7] - New orders signed in the first half of 2024 increased by over 15% year-over-year[22] - The company participated in 666 drug discovery projects in the first half of 2024, an increase of 16 projects year-over-year[27] - Laboratory services new orders increased by over 10% year-over-year, with biological sciences accounting for over 53% of laboratory services revenue[27] - CMC (small molecule CDMO) services new orders increased by over 25% year-over-year, with 78% of revenue coming from existing drug discovery service clients[28] - The company's laboratory services team consists of 9,377 employees, including nearly 6,000 laboratory chemistry researchers[28] - The company's CMC (small molecule CDMO) services team consists of 4,228 employees, with 695 drug molecules or intermediates involved in projects[29] - The company's clinical research services team consists of 3,899 employees, with a 96-bed early-stage clinical research center in Maryland, USA[31] - The number of ongoing clinical trial service projects reached 1,112, including 77 Phase III trials, 409 Phase I/II trials, and 626 other clinical trials[32] - The company provided efficacy determination and release services for 21 cell and gene therapy products from 17 clients, including 9 clinical-stage projects and 2 commercial projects[32] - The company's Carlsbad in vivo toxicology research center in California has been partially operational, supporting cell and gene therapy products, ophthalmic products, and medical devices[33] - The global biotech financing market showed signs of recovery, with increased funding for biotech companies, indicating a potential rebound in client demand[33] - The company's integrated platform offers end-to-end services from drug discovery to clinical development, with a strong presence in China, the US, and the UK[35] - The company's chemical technology platform covers the entire small molecule drug R&D process, from compound design to GMP-compliant commercial production[37] - The company's DMPK/ADME global service network includes advanced technologies like radioactive isotope analysis, enhancing its position as a leading integrated service provider[37] - Established a comprehensive drug discovery to clinical proof-of-concept integrated service platform, covering multiple disciplines such as drug molecule design, compound library synthesis, and clinical data statistics[38] - Built a domestic clinical research platform offering end-to-end services for Phase I-IV clinical development, enhancing competitiveness through internal growth and external acquisitions[38] - Developed a gene therapy "lab analysis-IND study-process development & production" integrated platform, including GLP/GCP/GMP-compliant facilities in the US and UK[40] - Operates 21 entities globally (11 overseas), leveraging international operations to provide customized services and solutions across key pharmaceutical regions[40] - Acquired advanced production equipment and leased a Singapore-based formulation factory, expanding global CDMO service capabilities[42] - Focused on innovation in chemical and biological technologies, including fluid chemistry, biocatalysis, and gene editing platforms[43] - Maintains a workforce of 18,241 R&D, production, and clinical service personnel across China, the UK, and the US as of June 30, 2024[44] - Strengthened international operations through strategic acquisitions, integrating top-tier talent and facilities into the integrated R&D service platform[41] - Collaborated with US-based clinical pharmacology teams to support domestic clients in filing IND applications and conducting first-in-human studies in the US[40] - Enhanced global service network by investing in PharmaGend and acquiring Strides Pharma Global's production assets in Singapore[42] - The company added over 360 new clients in the first half of 2024, with over 97% of revenue coming from repeat clients[46] - The company aims to strengthen its leadership in small molecule R&D services and expand into new drug fields such as oligonucleotides, peptides, antibodies, ADC, and cell and gene therapy products[69] - Kanglong Chem plans to enhance its CMC (small molecule CDMO) service competitiveness by integrating commercial capabilities in China, the UK, and the US, and improving resource utilization and production efficiency[69] - The company will focus on improving the integration of its clinical development platform, particularly enhancing collaboration between US and Chinese teams to support the global expansion of Chinese innovative drugs[70] - Kanglong Chem will continue to develop its large molecule and cell and gene therapy service platforms, expanding service content and increasing operational efficiency[70] - The company plans to strengthen talent acquisition and retention, particularly in drug R&D, and enhance internal training programs to support long-term sustainable development[71] - Kanglong Chem will further enhance the synergy of its integrated platform by improving management efficiency and reducing costs[71] - The company will intensify its business and market development efforts, particularly in overseas markets, by deepening customer relationships and expanding service offerings[72] - Kanglong Chem will prioritize production safety and intellectual property security, ensuring high-quality products and services while adhering to international quality standards[73] - The company plans to deepen its CRO+CDMO integrated platform and expand its customer base to strengthen its competitive position[79] - The company will invest heavily in new technologies and consider acquisitions to enhance its service capabilities[80] - Maintaining high service quality is crucial, as any failure could lead to client loss and reputational damage[80] Environmental, Social, and Governance (ESG) - The company's ESG initiatives reduced carbon emissions by 15% compared to the previous year[7] - The company's ESG rating was upgraded to AA, and it was included in the 2024 A-share listed companies ESG Excellence TOP100 and Corporate Governance (G) Dimension Best Practice TOP20[26] - The company adheres to environmental protection laws and regulations in China, the UK, and the US, including the Clean Water Act and Clean Air Act[96] - Completed environmental self-acceptance for the application of biological in vitro test models to study drug efficacy and druggability platform project on April 13, 2023[98] - Obtained the first pollutant discharge permit on October 14, 2019, with the current permit valid until October 13, 2027[98] - Completed environmental self-acceptance for the new drug R&D outsourcing service base expansion project in Tianjin in November 2022[99] - Received approval for hazardous waste transfer to Hebei Province for utilization on January 24, 2024, with approval number Jinkaihuan Guzhuan [2024]10[100] - Received approval for hazardous waste transfer to Shandong Province for utilization on March 14, 2024, with approval number Jinkaihuan Guzhuan [2024]30[100] - Reapplied and obtained approval for the pollutant discharge permit on June 6, 2024[100] - Approved for the environmental impact assessment of the Xi'an R&D Center (Phase II) project on December 30, 2015, with approval number Jingkaihuan Pifu [2015]235[101] - Obtained the pollutant discharge permit for Xi'an on December 14, 2020, valid until December 13, 2023[101] - Completed environmental self-acceptance for the new drug R&D outsourcing platform expansion project in Beijing on August 20, 2020[97] - Approved for the environmental impact assessment of the new drug R&D outsourcing platform in vitro pharmacokinetics project on November 20, 2020, with approval number Jinghuan Shenzi [2020]0093[97] - The company completed the environmental protection acceptance monitoring report for the 120 tons/day laboratory wastewater treatment project at Kanglong Huacheng (Xi'an) New Drug Technology Co., Ltd., which was approved by the expert group[102] - The company obtained a pollutant discharge permit for Kanglong Huacheng (Xi'an) New Drug Technology Co., Ltd., valid until December 13, 2028[102] - The company completed the environmental impact assessment and acceptance monitoring reports for multiple projects in the Hangzhou Bay Life Science Park, including the bio-pharmaceutical R&D base and animal laboratory public service platform[103] - The company obtained environmental impact assessment approvals for the second phase of the Hangzhou Bay Life Science Industrial Park bio-pharmaceutical R&D service base project[103] - The company completed the environmental impact assessment and acceptance monitoring reports for the annual production of 47 tons and 25 tons of pharmaceutical intermediates at Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd.[104] - The company obtained a pollutant discharge permit for Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd., valid until October 10, 2026[104] - The company completed the environmental protection facility acceptance report for the annual production of 25 tons of pharmaceutical intermediates at Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd.[105] - The company obtained environmental impact assessment approvals for the new drug development technology service platform project at Kanglong Huacheng (Beijing) Technology Development Co., Ltd.[106] - The company completed the environmental impact assessment and adjustment report for the innovation center bio-pharmaceutical innovation platform project at Kanglong Huacheng (Ningbo) Bio-pharmaceutical Co., Ltd.[106] - The company reported the discharge of major pollutants, including CODcr, PH, NH3-N, and SS, at Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd., with no超标排放情况[107] - Average concentration of VOCs emissions is 1.435 mg/m³, with a total emission of 11.28 tons[108] - Average concentration of nitrogen oxides emissions is 17 mg/m³, with a total emission of 0.2737 tons[108] - Total emission of waste organic solvents is 2094.547 tons[108] - Total emission of contaminated waste packaging is 606.45 tons[108] - Total emission of waste activated carbon is 14.836 tons[108] - Total emission of waste silica gel is 64.676 tons[108] - Total emission of laboratory waste is 20.475 tons[108] - Total emission of waste oil is 0 tons[109] - Total emission of expired and invalid drugs is 0 tons[109] - Total emission of COD

证券代码:300759 证券简称:康龙化成 公告编号:2024-048 康龙化成(北京)新药技术股份有限公司 2024年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 以下为本公司的 2024 年半年度业绩预告。本业绩预告所载之财务数据未经 审计,除经调整的非《国际财务报告准则》下归属于上市公司股东的净利润或另 有注释外,本业绩预告所载之财务数据根据中国企业会计准则编制。 一、本期业绩预计情况 1、业绩预告期间 2024 年 1 月 1 日至 2024 年 6 月 30 日 2、业绩预告情况 预计归属于上市公司股东的净利润同向上升,预计营业收入、归属于上市公 司股东的扣除非经常性损益后的净利润以及经调整的非《国际财务报告准则》下 归属于上市公司股东的净利润同向下降。 项 目 本报告期 上年同期 营业收入 营收:547,091.46 万元–564,011.81 万元 营收:564,011.81 万元 比上年同期下降:0%–3% 盈利:105,515.08 万元–114,287.55 万元 盈利:78,609.30 万元 比上年同期增长:34%–4 ...

Financial Performance - In 2023, the company achieved a revenue of RMB 11,538.0 million, representing a year-on-year growth of 12.4%[6] - The net profit attributable to shareholders was RMB 1,601.1 million, an increase of 16.5% compared to the previous year[6] - The net cash flow from operating activities reached RMB 2,753.5 million, up by 28.5% year-on-year[6] - Total revenue for the year ended December 31, 2023, was approximately RMB 11,538 million, an increase of about RMB 1,272 million or 12.4% compared to the previous year[10] - Gross profit for the same period was RMB 4,095 million, reflecting a growth of 9.2% from RMB 3,749 million in 2022[10] - Adjusted net profit under non-IFRS was RMB 1,903 million, a slight increase of 3.8% from RMB 1,834 million in 2022[10] - The profit attributable to the owners of the parent company was approximately RMB 1,601.1 million, an increase of about 16.5% compared to the year ended December 31, 2022[11] - The net cash flow from operating activities was approximately RMB 2,753.5 million, an increase of about 28.5% compared to the year ended December 31, 2022[11] Assets and Liabilities - By the end of 2023, total assets amounted to RMB 26,476.7 million, reflecting a growth of 29.2% from the beginning of the year[6] - The net assets attributable to shareholders were RMB 12,556.8 million, which is a 19.0% increase from the start of the year[6] - Total liabilities rose to RMB 13,238.667 million in 2023, compared to RMB 9,652.689 million in 2022[13] - The total current assets as of December 31, 2023, were approximately RMB 10,874.4 million, compared to RMB 6,536.0 million as of December 31, 2022[31] - The current ratio as of December 31, 2023, was approximately 3.0, compared to 1.7 as of December 31, 2022[31] Workforce and Operations - The workforce as of December 31, 2023, totaled 20,295 employees, with 89.87% engaged in R&D, production technology, and clinical services[8] - The total number of employees increased by 814 to 20,295, with R&D, production technology, and clinical service personnel making up 89.9% of the workforce[21] - The company operates 21 R&D service centers and production bases across China, the UK, and the US, providing innovative drug development solutions[6] - The company has a workforce of 9,466 employees in laboratory services, with over 6,000 laboratory chemists, positioning it as a leader in scale and experience globally[22] Research and Development - The company is diversifying its service offerings, expanding into new drug areas including small nucleic acids, peptides, antibodies, and ADC drugs[6] - The company continues to enhance its traditional small molecule drug development services while integrating new technologies[6] - The company participated in 764 small molecule drug discovery projects in 2023, maintaining growth in this segment[7] - The company’s integrated service platform has enhanced its competitive advantage in drug development, particularly in small molecule drug discovery and new drug modalities[7] - The company is focused on developing and producing gene and cell therapy products, meeting specific analytical requirements for clinical development[19] Client Base and Market Presence - The company expanded its customer base, adding over 800 new clients, with active clients exceeding 2,800[6] - Revenue from North American customers was RMB 7,400.8 million, an increase of 11.4%, accounting for 64.1% of total revenue[21] - The company served over 2,800 global customers, with those using multiple business segments contributing RMB 8,641.1 million, or 74.9% of total revenue[20] - New customers added during the reporting period exceeded 800, contributing RMB 858.7 million, which accounted for 7.4% of total revenue[20] Corporate Governance and Management - The board of directors was reduced from 11 to 9 members, with 3 executive directors, 2 non-executive directors, and 4 independent non-executive directors[36] - The company emphasizes a "people first, customer-centered" philosophy, focusing on employee development and improving mechanisms for personal career growth[54] - The board has established four specialized committees to oversee specific aspects of corporate governance[92] - The company has a strong management team, including Mr. Lou as COO and Ms. Zheng as Executive Vice President, both of whom have extensive backgrounds in their respective fields[72][73] Environmental, Social, and Governance (ESG) - The company is actively enhancing its ESG performance and has initiated ISO 14001 environmental management system certification[21] - The company has been recognized with multiple awards for its ESG efforts, including being rated as a "low-risk" company by Sustainalytics and included in the ESG Top 50 for Chinese listed companies[22] - The company is committed to environmental protection, health, safety, and intellectual property rights, ensuring the protection of clients' intellectual property[55] Future Outlook and Strategy - The company aims to enhance its service capabilities and management efficiency to meet market and customer demands through integrated drug research and development services[16] - The company plans to continue enhancing its R&D capabilities in large molecules and cell and gene therapy services[34] - The company aims to strengthen its CMC (small molecule CDMO) service competitiveness and expand into new drug areas such as oligonucleotides, peptides, antibodies, ADCs, and cell and gene therapies[58] - The company will continue to focus on "full-process, integrated, and international" development strategies to enhance service quality and gain market share in the pharmaceutical health industry[58] Financial Management and Investments - The company has implemented a series of financing and fiscal policies to manage its capital resources and mitigate related risks[33] - The company completed a capital increase agreement with Kanglong Biotech for a total consideration of approximately RMB 950 million on September 19, 2023[34] - The company has pledged deposits of approximately RMB 127.7 million for issuing letters of credit and environmental protection as of December 31, 2023, compared to RMB 49.3 million on December 31, 2022[33] - The company plans to utilize RMB 377.6 million for operational working capital and other general corporate purposes, with 100% of the funds expected to be utilized by December 31, 2023[144] Risk Management - The company has established a risk management system aimed at enhancing risk prevention capabilities and promoting sustainable development[114] - The internal audit system is designed to improve the quality and efficiency of internal audits, thereby enhancing the company's supervision and risk control mechanisms[114] - The company employs a combination of qualitative and quantitative methods for risk analysis, prioritizing risks based on their likelihood and impact[117] Shareholder Relations - The board of directors will continue to enhance investor relations management in 2024, focusing on proactive communication through various channels[129] - The company has adopted a shareholder communication policy, which was reviewed and deemed effective by the board on March 27, 2024[129] - The company reported a net amount of approximately RMB 4,522.7 million raised from the global offering, fully utilized as per the prospectus dated November 14, 2019[135]

Investment Rating - The investment rating for the company is "Buy" with a target price of 27.44, maintaining the previous rating of "Buy" [1]. Core Views - The report highlights an improvement in new order signing, with expectations for sequential performance recovery. The integrated transformation logic continues to be validated, supporting a positive long-term growth outlook for the company [1]. Summary by Sections Financial Performance - In Q1 2024, the company's revenue was 26.71 billion yuan, a decrease of 1.95% year-on-year, while the net profit attributable to shareholders was 2.31 billion yuan, down 33.80% year-on-year. Adjusted net profit was 3.39 billion yuan, reflecting a decline of 22.7% year-on-year. The performance met expectations despite a one-time loss from the integration and closure of a laboratory in Shanghai, increased employee costs, and a decrease in the fair value of biological assets [1]. - The company expects EPS for 2024-2026 to be 0.98, 1.13, and 1.35 yuan, respectively, maintaining the target price of 27.44 yuan [1]. Business Segments - The laboratory services segment generated revenue of 16.05 billion yuan, down 2.9%, with a gross margin of 44.14%, a decrease of 0.34 percentage points. The new order growth rate improved to over 20% [1]. - The small molecule CDMO business revenue was 5.82 billion yuan, down 2.7%, affected by project delivery schedules, with a gross margin of 27.90%, down 5.05 percentage points. The clinical research services revenue was 3.92 billion yuan, up 4.6%, primarily due to overseas clinical trial contributions [1]. Client and Project Growth - The company has steadily expanded its client base, with over 800 new clients added, including process validation and commercialization projects. Active clients increased to over 2,800, with 29 active clients in clinical phase III services [1]. - The company has successfully completed on-site inspections and compliance checks for its formulation workshop, indicating that backend capabilities are expected to gradually materialize [1]. Market Position - The company is recognized as the second-largest pharmaceutical R&D service platform in China and one of the top three drug discovery service providers globally, with a revenue growth rate of 37.9% as of 2018 [3].

Financial Performance - The company's revenue for Q1 2024 was CNY 2,670,740,738.16, a decrease of 1.95% compared to CNY 2,723,970,949.97 in the same period last year[8] - Net profit attributable to shareholders was CNY 230,557,834.70, down 33.80% from CNY 348,255,328.87 year-on-year[8] - The adjusted net profit attributable to shareholders was CNY 338,816,299.13, reflecting a decrease of 22.70% compared to CNY 438,339,247.42 in the previous year[8] - Operating profit decreased to CNY 268,414,806.18, down 37.8% from CNY 431,571,732.74 in the previous period[43] - Net profit for the current period was CNY 215,919,833.12, a decline of 38.2% compared to CNY 350,146,873.58 in the previous period[44] - Basic earnings per share decreased by 33.94% to ¥0.1300, driven by the reduction in net profit attributable to shareholders[16] - Diluted earnings per share fell by 34.01% to ¥0.1298, also reflecting the decrease in net profit attributable to shareholders[18] - Basic earnings per share for the current period was CNY 0.1300, down from CNY 0.1968 in the previous period[46] - The company reported a net profit of RMB 215,920,000 for the current period, down 38.3% from RMB 350,148,000 in the previous year[53] - The company's basic earnings per share for the current period was RMB 0.1300, down from RMB 0.1968 in the previous year[53] Cash Flow and Assets - Cash flow from operating activities increased by 40.65% to CNY 745,630,586.78, up from CNY 530,139,954.34 in the same period last year[8] - Net cash flow from operating activities increased by 40.65% to ¥745,630,586.78, mainly due to an increase in sales collections[16] - Cash and cash equivalents decreased from CNY 5,918,915,276.72 to CNY 4,633,337,568.45, representing a decrease of about 21.7%[36] - The total current assets decreased from CNY 10,874,413,206.01 to CNY 9,448,379,249.76, a decline of approximately 13.1%[36] - The total assets at the end of the reporting period were CNY 25,243,967,050.83, a decrease of 4.66% from CNY 26,476,712,835.60 at the end of the previous year[8] - The total assets decreased from CNY 26,476,712,835.60 to CNY 25,243,967,050.83, a decline of about 4.7%[37] - The total assets less current liabilities amounted to RMB 21,487,864,000, a decrease from RMB 22,822,237,000 at the end of the previous period[54] Liabilities and Equity - Total liabilities decreased to CNY 11,886,956,291.91 from CNY 13,238,666,497.83, reflecting a reduction of 10.2%[41] - Non-current liabilities totaled CNY 8,130,853,112.80, down 15.2% from CNY 9,584,190,645.48[41] - The total equity attributable to the parent company increased to CNY 12,687,089,142.67 from CNY 12,556,797,361.42, a rise of 1.04%[41] - The total equity attributable to the owners of the parent company was RMB 12,687,089,000, up from RMB 12,556,797,000, indicating an increase of 1.0%[55] Operational Highlights - The company signed new orders that increased by over 20% compared to the same period last year, indicating a recovery in customer inquiries and visits[11] - The gross profit margin for laboratory services was 44.14%, slightly down from 44.48% in the previous year[11] - The gross profit margin for clinical research services improved to 9.32%, up from 14.02% year-on-year[11] - Total operating costs increased to CNY 2,439,362,705.75, up 3.69% from CNY 2,352,273,096.85 in the previous period[43] Research and Development - Research and development expenses increased to CNY 93,605,963.99, up 22% from CNY 76,838,901.31 in the previous period[43] - Research and development expenses increased to RMB 93,606,000, compared to RMB 76,839,000 in the same period last year, reflecting a growth of 22%[53] Other Financial Metrics - The company reported a net profit from non-operating income of CNY 43,209,069.08 for the period[14] - Investment income surged by 177.35% to ¥46,569,164.93, attributed to the repurchase of certain convertible bonds during the reporting period[20] - Other comprehensive income decreased significantly by 1,136.05% to -¥59,702,067.74, mainly due to changes in cash flow hedging reserves[20] - The company reported a foreign exchange-related gain of RMB 25,063,000 in Q1 2024, compared to a loss of RMB 804,000 in the same period last year[58] - The company incurred a one-time loss of RMB 44,016,000 due to the closure of Kanglong Chemical (Shanghai) New Drug Technology Co., Ltd.[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 85,011[24] - The number of shares held by the top 10 unrestricted shareholders includes HKSCC NOMINEES LIMITED with 301,502,043 shares[26] - The company plans to release restricted shares for certain executives, with a total of 6,986,213 shares being released this period[32] - The company has ongoing stock incentive plans for 2021 and 2022, with announcements regarding vesting results expected in January 2024[34]